Trial Profile
A Phase 1 Study of Fosbretabulin in Combination With Everolimus in Neuroendocrine Tumors (Grades 1-3) That Have Progressed After at Least One Prior Regimen for Metastatic Disease
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 Aug 2019
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Fosbretabulin (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions
- 06 Aug 2019 Status changed from active, no longer recruiting to discontinued.
- 04 Jun 2019 Results (n=17) presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO 2019).
- 03 Apr 2019 Results assessing safety and tolerability of Fosbretabulin in combination with everolimus in neuroendocrine tumors presented at the 110th Annual Meeting of the American Association for Cancer Research